| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Research Abstract |
A novel Insulin-like growth factor-1(IGF-1), which has heparinbinding domain was designed and purified. In vitro the novel IGF-1 binds with the surface of cell membrane, because heparinbinding domain can bind with negatively charged Proteoglycan. We checked the new IGF-1 effect with peripheral artery disease model, but we could not see the long time effect in vivo. We need to improve the drug delivery system in vivo. These results showed the new strategy of drug delivery system.
|
